Clinical Trial Detail

NCT ID NCT03207555
Title Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult senior

No variant requirements are available.